Anti-CD3-folate conjugates and their uses
Inventors
Rashid, Harun • Tian, Feng • Gymnopoulos, Marco
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.
Core Innovation
The invention relates to anti-human CD3 antibody conjugates that include non-naturally encoded amino acids and enable site-selective attachment at specific positions of a heavy chain variable or heavy chain sequence, namely position 114Ala, position 115Ser, or position 129Lys. The non-naturally encoded amino acid is para-acetyl-phenylalanine, para-azido-phenylalanine, or p-propargyloxyphenylalanine. The antibody sequences are defined using heavy chain amino acid sequences selected from SEQ ID NOs: 1, 2, and 3 and light chain amino acid sequences selected from SEQ ID NOs: 4, 5, and 6.
The document also discloses a bispecific binding molecule that includes a first binding domain that is folate and specifically binds to a folate receptor, and a second binding domain defined by the specified anti-CD3 heavy and light chain sequences with a non-naturally encoded amino acid substituted at one of the defined heavy chain positions. The disclosed bispecific binding molecule can include attachment structures such as a linker, a polymer, or a biologically active molecule. Dependent embodiments specifically describe folate attachment to the non-naturally encoded amino acid.
In described constructs and conjugates, the non-naturally encoded amino acid, including para-acetyl-phenylalanine, is used to enable folate-linker conjugation, producing an anti-CD3 Fab-folate conjugate. The described constructs include folate-PEG conjugate intermediates and final constructs, including a folate-PEG aminooxy linker and folate-lys-PEG4-aminooxy linker, used to form an anti-CD3 Fab-folate conjugate.
Claims Coverage
The independent claims cover three related inventions: an anti-human CD3 antibody with defined heavy and light chain sequence selections plus a non-naturally encoded amino acid at one of defined heavy-chain positions, a bispecific binding molecule that combines a folate or folate receptor binding domain with the defined anti-CD3 binding domain, and an anti-human CD3 antibody defined at the binding-domain level. Across these independent claims, inventive features are centered on sequence-defined CD3-binding domains and positional non-naturally encoded amino acid substitution, with folate receptor binding in the bispecific claim.
Non-naturally encoded amino acid substituted at defined heavy-chain positions in an anti-human CD3 antibody
An anti-human CD3 antibody comprising a heavy chain amino acid sequence selected from SEQ ID NOs: 1, 2 and 3, a light chain amino acid sequence selected from SEQ ID NOs: 4, 5 and 6, and a non-naturally encoded amino acid substituted for position 114Ala, position 115Ser, or position 129Lys of the heavy chain, wherein the non-naturally encoded amino acid is para-acetyl-phenylalanine, para-azido-phenylalanine or p-propargyloxyphenylalanine.
Bispecific binding molecule combining folate receptor binding with an anti-human CD3 binding domain defined by non-naturally encoded amino acid substitution
A bispecific binding molecule comprising a first binding domain that is folate and specifically binds to a folate receptor, and a second binding domain comprising a heavy chain amino acid sequence selected from SEQ ID NOs: 1, 2 and 3, a light chain amino acid sequence selected from SEQ ID NOs: 4, 5 and 6, and a non-naturally encoded amino acid substituted for position 114Ala, position 115Ser, or position 129Lys of the heavy chain, wherein the non-naturally encoded amino acid is para-acetyl-phenylalanine, para-azido-phenylalanine or p-propargyloxyphenylalanine.
Binding domain architecture for an anti-human CD3 antibody with defined variable domains and non-naturally encoded amino acid substitution
An anti-human CD3 antibody wherein the anti-human CD3 antibody comprises a binding domain comprising a variable heavy chain domain comprising an amino acid sequence selected from SEQ ID NOs: 1, 2 and 3, a variable light chain domain comprising an amino acid sequence selected from SEQ ID NOs: 4, 5 and 6, and a non-naturally encoded amino acid substituted for position 114Ala, position 115Ser, or position 129Lys of the variable heavy chain domain, wherein the non-naturally encoded amino acid is para-acetyl-phenylalanine, para-azido-phenylalanine or p-propargyloxyphenylalanine.
Overall, the independent claim set is directed to CD3-binding antibodies defined by specific SEQ ID selections for heavy and light chain sequences, with non-naturally encoded amino acid substitution at defined heavy-chain positions using para-acetyl-phenylalanine, para-azido-phenylalanine, or p-propargyloxyphenylalanine, and to a bispecific binding molecule in which this anti-CD3 binding domain is combined with a folate or folate receptor-binding domain.
Stated Advantages
Not explicitly described in patent.
Documented Applications
In vitro efficacy using folate receptor expression and cytotoxicity readouts associated with the anti-CD3 Fab-folate conjugate.
Pharmacokinetic study in rats via ELISA quantification associated with the conjugate.
In vivo NOD-SCID mouse tumor efficacy with PBMC co-implantation and IV dosing associated with the anti-CD3 Fab-folate conjugate, including tumor growth measurement and immunohistochemistry (H&E).
Interested in licensing this patent?